Biostage (BSTG) Stock Price, News & Analysis

Company Overview

Biostage, Inc. (OTCMKTS: BSTG) is a development‐stage regenerative medicine company dedicated to creating implantable, tissue‐engineered medical devices designed to treat severe organ disorders. The company’s proprietary platform integrates bioscaffolds with a patient’s own cells to produce living implants that can restore structure and function in damaged tissues. Biostage’s mission focuses on addressing unmet medical needs in life‐threatening conditions where conventional therapies offer limited efficacy.

The company’s lead product candidate, the Neo‐Esophagus, is designed to replace or repair sections of the esophagus damaged by congenital defects, cancer resections, or severe trauma. Biostage also has earlier‐stage programs targeting airway reconstruction, leveraging the same scaffold‐and‐autologous‐cell technology. By using a patient’s own cells, the company aims to reduce the risk of rejection and eliminate the need for long‐term immunosuppression. Biostage has secured regulatory clearance to initiate clinical studies for its esophageal repair device and continues to advance its pipeline through preclinical development.

Founded in 2003 under the name Tengion, the company rebranded as Biostage in 2018 to reflect its focus on true tissue regeneration and organ reconstruction. Headquartered in Cambridge, Massachusetts, Biostage operates within the United States, collaborating with research institutions and clinical investigators to drive its development programs forward. The company is led by a management team with extensive experience in biotechnology, medical devices, and regenerative medicine, positioning Biostage to translate its novel platform into potential therapies for patients with critical organ needs.

Key Stats

• Today's Range: $4.45 to $4.45
• 50-Day Range: $4.45 to $4.45
• 52-Week Range: $4.45 to $4.45
• Volume: N/A
• Average Volume: 1,847 shs
• Market Capitalization: $61.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

BSTG Stock Analysis - Frequently Asked Questions

How have BSTG shares performed this year?

Biostage's stock was trading at $4.45 on January 1st, 2025. Since then, BSTG shares have increased by 0.0% and is now trading at $4.45.

How were Biostage's earnings last quarter?

Biostage, Inc. (OTCMKTS:BSTG) announced its earnings results on Thursday, August, 13th. The company reported ($0.14) EPS for the quarter.

How do I buy shares of Biostage?

Shares of BSTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biostage own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biostage investors own include Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), Ashford Hospitality Trust (AHT), Assertio (ASRT), Adaptimmune Therapeutics (ADAP), PlayAGS (AGS) and Akebia Therapeutics (AKBA).

Company Calendar

• Last Earnings: 8/13/2020
• Today: 10/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:BSTG
• CIK: 1563665
• Web: www.biostage.com
• Phone: (744) 233-7300
• Fax: 774-233-7302
• Employees: 7
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -174.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.73
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.26) per share
• Price / Book: -17.12

Miscellaneous

• Outstanding Shares: 13,882,000
• Free Float: 11,758,000
• Market Cap: $61.77 million
• Optionable: Not Optionable
• Beta: -1.02